预约演示
更新于：2026-02-02
Isavuconazonium Sulfate
硫酸艾沙康唑
更新于：2026-02-02
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (澳大利亚) |
登录后查看时间轴
结构/序列
分子式C35H36F2N8O9S2 |
InChIKeyLWXUIUUOMSMZKJ-KLFWAVJMSA-M |
CAS号946075-13-4 |
关联
68
项与 硫酸艾沙康唑 相关的临床试验NCT07080359
Isavuconazole in Critically Ill Patients: A Study on Antifungal Efficacy and Safety
CTR20251823
评估受试制剂硫酸艾沙康唑胶囊（规格：0.1g）与参比制剂硫酸艾沙康唑胶囊（CRESEMBA®/康新博®）（规格：100 mg）在健康成年研究参与者空腹及餐后状态下的单中心、随机、开放、两制剂、两周期交叉、单剂量给药生物等效性试验。
NCT07191756
A Retrospective, Multicenter Cohort Study Comparing the Efficacy and Safety of Amphotericin B Versus Isavuconazole for the Treatment of Mucormycosis: Analysis of Institutional Data and Literature Review
100 项与 硫酸艾沙康唑 相关的临床结果
登录后查看更多信息
100 项与 硫酸艾沙康唑 相关的转化医学
登录后查看更多信息
100 项与 硫酸艾沙康唑 相关的专利（医药）
登录后查看更多信息
731
项与 硫酸艾沙康唑 相关的文献（医药）2026-03-01JOURNAL DE MYCOLOGIE MEDICALE
Probable disseminated cryptococcosis relapse in a patient with Hodgkin's lymphoma treated with induction therapy resumption and autologous stem cell transplant
Article
作者: Sabouni, Zeina ; Schiano, Jean Marc ; Sevestre, Jacques ; Berger, Pierre ; Deschamps, Anthéa ; Berro, Simar ; Solas, Caroline ; Marchand, Océane ; Bes-Berlandier, Hugo ; Ranque, Stephane ; Choufi, Bachra ; Imbert, Guenièvre ; L'ollivier, Coralie ; Ramtohul, Prithvi ; Guilhaumou, Romain ; Menu, Estelle ; Stellmann, Jan Patrick ; Granata, Angela ; Legrand, Faezeh ; Sohn, Claudine
Cryptococcus species are fungi that primarily cause infections in immunocompromised patients. In cases of hematologic malignancies, it can result in central nervous system and disseminated infections which are associated with high morbidity and case-fatality rate. We present the case of a patient with Hodgkin's lymphoma who experienced a probable relapse in disseminated cryptococcosis during the consolidation phase of treatment. After prolonged induction therapy with amphotericin B and flucytosine, followed by isavuconazole maintenance, the patient achieved a favourable outcome. Six months after relapse of cryptococcosis, the patient underwent autologous stem cell transplantation (ASCT), which resulted in sustained lymphoma remission. The cryptococcosis was successfully contained. This case highlights the need for clinicians to consider reintroducing IT in patients who experience clinical and radiological worsening during the consolidation phase. The patient demonstrated sustained clinical and radiological improvement at seven months post-ASCT, notwithstanding the presence of active cryptococcosis. This suggests that ASCT appears to be safe and feasible when the prognosis of the underlying hematological malignancy warrants its use.
2026-02-01MYCOPATHOLOGIA
Concurrent Administration of Triazoles with Chemotherapeutic and/or Immunosuppressant Agents Known to Have Moderate-to-Severe Drug-Drug Interactions in Patients with Hematologic Malignancies Hospitalized for Invasive Aspergillosis
Article
作者: Walsh, Thomas J ; Coleman, Craig I ; Johnson, Melissa D ; Alexander, Barbara D ; Lovelace, Belinda
Abstract:
Background:
Triazoles are widely used for treatment and prevention of invasive aspergillosis (IA) but can cause serious drug-drug interactions (DDIs) with chemotherapeutic (CT) and immunosuppressant (IS) agents via CYP3A4 inhibition. The frequency of triazole-CT or IS concurrent administration in hematologic malignancies (HM) patients newly admitted with IA is largely unknown.
Methods:
We studied US IQVIA claims including adults with ≥ 1 claim for an inpatient stay with a diagnosis code for IA from October 1, 2015-November 30, 2022 and evidence of systemic antifungal therapy for ≥ 3 days during the hospitalization. The cohort was limited to patients with ≥ 1 HM diagnosis code within 6 months prior to IA admission. Utilization of triazoles with CT and/or ISs known to have moderate-to-severe pharmacokinetic (PK) interactions was described.
Results:
Triazoles, predominantly isavuconazole (61.0%) and voriconazole (53.6%), were administered in 97.2% of 317 patients with IA. Of these, 241 (78.2%) received an interacting CT and/or IS. Potentially interacting agents administered with a triazole included corticosteroids (70.8%), calcineurin or mammalian target of rapamycin (mTOR) inhibitors (25.0%) (84.4% tacrolimus), alkylating agents (14.0%) (76.7% cyclophosphamide), venetoclax (9.7%), anthracyclines (6.2%), and vincristine (5.8%).
Conclusions:
Concurrent administration of triazole with potential PK interactions with CT or IS agents occurred in most HM patients admitted for IA. Choosing alternative antifungals, therapeutic drug monitoring of triazoles or selective ISs, and dosage adjustment of CT/IS agents may mitigate the risk of adverse DDIs. New antifungal agents without serious DDIs with CT and/or IS agents are needed for treatment of IA to reduce the risk of serious adverse events.
2026-02-01CLINICAL MICROBIOLOGY AND INFECTION
Relative contributions of the ERG11VF125AL and MRR1AN647T mutations to fluconazole resistance in Clade III Candidozyma (Candida) auris clinical isolates
Article
作者: Barker, Katherine S ; Zhang, Qing ; Rybak, Jeffrey M ; Morschhäuser, Joachim ; Cuomo, Christina A ; Rogers, P David ; Peters, Tracy L
OBJECTIVES:
Candidozyma (Candida) auris is an emerging fungal pathogen of global concern that often exhibits multidrug resistance. Of the six described C. auris clades, Clade III has been found to be nearly universally fluconazole resistant, and almost every Clade III isolate described carries a mutation leading to a VF125AL substitution in ERG11, the gene encoding the fluconazole target lanosterol 14α-demethylase, and a mutation leading to a N647T substitution in the gene encoding Mrr1a, a transcriptional regulator of the Mdr1 transporter. In this study, we aimed to determine the specific contributions of these mutations to triazole antifungal susceptibility in Clade III C. auris isolates.
METHODS:
We introduced the Clade III MRR1A mutation into a Clade I background using CRISPR-Cas9 gene editing. In two Clade III clinical isolates, we corrected the native MRR1A and ERG11 mutations to their wild-type sequences, as well as disrupted MDR1. Triazole susceptibilities and MDR1 gene expression were measured in all strains.
RESULTS:
Introduction of the N647T substitution in a Clade I background increases fluconazole MIC from 2 to 4 μg/mL. Correction of MRR1A or disruption of MDR1 in each Clade III background resulted in a one-dilution decrease in fluconazole MIC (64-32 μg/mL), whereas the ERG11 correction resulted in a three-to four-dilution decrease (64 to 4-8 μg/mL) in fluconazole MIC. Correction of both mutations together resulted in a further decrease to 4 μg/mL. Similar changes were observed for voriconazole.
CONCLUSIONS:
Our findings show that although the MRR1A mutation makes a modest contribution, the ERG11 mutation is responsible for most of the fluconazole resistance observed in Clade III isolates. We also show that although these mutations likewise affect voriconazole susceptibility, they have no effect on itraconazole, isavuconazole, or posaconazole susceptibility, suggesting the therapeutic utility of these antifungals for infections due to Clade III C. auris isolates.
100 项与 硫酸艾沙康唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 隐球菌病 | 日本 | 2022-12-23 | |
| 曲霉菌病 | 加拿大 | 2018-12-19 | |
| 侵袭性曲霉菌病 | 美国 | 2015-03-06 | |
| 毛霉菌病 | 美国 | 2015-03-06 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 侵袭性真菌感染 | 申请上市 | 日本 | 2022-01-30 | |
| 新型冠状病毒感染 | 临床3期 | 美国 | 2021-03-16 | |
| 肺曲霉菌病 | 临床3期 | 美国 | 2021-03-16 | |
| 深部真菌病 | 临床3期 | 日本 | 2018-04-16 | |
| 念珠菌血症 | 临床3期 | 美国 | 2007-03-08 | |
| 念珠菌血症 | 临床3期 | 美国 | 2007-03-08 | |
| 念珠菌血症 | 临床3期 | 中国 | 2007-03-08 | |
| 念珠菌血症 | 临床3期 | 中国 | 2007-03-08 | |
| 念珠菌血症 | 临床3期 | 阿根廷 | 2007-03-08 | |
| 念珠菌血症 | 临床3期 | 阿根廷 | 2007-03-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 8,068 | 網襯選餘範遞範蓋鹽遞(蓋窪遞餘壓廠網積繭鹽) = 願窪顧醖齋遞築獵廠廠 顧積壓糧繭積艱壓淵鹹 (衊範簾遞襯醖膚構鏇鹹 ) 更多 | 积极 | 2025-12-06 | |||
網襯選餘範遞範蓋鹽遞(蓋窪遞餘壓廠網積繭鹽) = 範艱顧蓋構鬱糧遞鬱獵 顧積壓糧繭積艱壓淵鹹 (衊範簾遞襯醖膚構鏇鹹 ) 更多 | |||||||
N/A | 295 | 繭夢憲襯壓艱艱齋觸壓(糧醖襯糧願齋憲構鏇鏇) = 網夢願壓鑰遞淵獵構襯 糧願顧蓋夢齋積夢選築 (鬱簾願齋齋鬱鏇繭壓選 ) 更多 | 积极 | 2024-12-07 | |||
繭夢憲襯壓艱艱齋觸壓(糧醖襯糧願齋憲構鏇鏇) = 鹽鹽觸繭廠夢廠蓋衊艱 糧願顧蓋夢齋積夢選築 (鬱簾願齋齋鬱鏇繭壓選 ) 更多 | |||||||
N/A | - | 218 | Isavuconazole monotherapy | 繭鬱襯糧願襯構餘壓積(鹽築鏇廠積膚獵鬱鑰壓) = 45 patients (21%) experienced at least one adverse event (AE) 鏇願壓齋願艱顧糧鏇襯 (鬱壓鬱廠獵襯製壓窪遞 ) 更多 | 积极 | 2024-12-01 | |
Salvage therapy | |||||||
临床2期 | 31 | 築築膚範窪範醖製簾鬱 = 積鏇顧壓壓襯鏇齋獵淵 窪艱鏇蓋壓艱餘繭積壓 (襯鑰膚簾膚齋壓廠鹽艱, 窪繭製選遞獵壓繭築獵 ~ 膚繭廠鬱網選願衊選餘) 更多 | - | 2023-09-21 | |||
N/A | 50 | 憲鹹選夢選繭顧淵構憲(鑰廠壓齋繭衊齋夢繭觸) = No adverse events related to ISA were reported 餘廠鹽繭網範蓋顧廠鑰 (觸網鏇繭淵簾憲襯蓋齋 ) | - | 2023-04-23 | |||
临床3期 | 103 | 鹹築製鹽獵壓鏇積餘廠(窪繭鹹齋顧壓齋獵積製) = Adverse drug reactions were reported in 32 (61.5%) patients receiving isavuconazole and 23 (85.2%) patients receiving voriconazole 築艱膚襯顧鏇餘淵構獵 (鏇製膚廠鏇齋築製築鏇 ) 更多 | 积极 | 2022-10-25 | |||
N/A | 166 | 衊鏇網鏇製艱鹽糧襯簾(淵壓鑰製衊餘醖膚網艱) = 齋窪觸築蓋鬱鬱廠築膚 積獵積蓋餘鏇獵鹽壓鬱 (醖蓋餘觸壓廠醖獵鬱築 ) 更多 | - | 2022-03-19 | |||
衊鏇網鏇製艱鹽糧襯簾(淵壓鑰製衊餘醖膚網艱) = 鏇艱衊獵艱觸廠積鬱鹹 積獵積蓋餘鏇獵鹽壓鬱 (醖蓋餘觸壓廠醖獵鬱築 ) 更多 | |||||||
临床2期 | 65 | 遞鏇積壓繭鑰範窪衊窪 = 選鏇鹹遞積積鹹廠憲選 艱衊襯遞憲壓範餘齋鹹 (艱鹽壓鑰簾網淵簾餘範, 淵願齋襯艱獵廠窪範鹽 ~ 襯夢獵範遞簾衊窪淵醖) 更多 | - | 2021-09-24 | |||
临床2期 | 75 | 鹽壓壓獵鏇鹽鹽廠膚構(願醖築願顧衊餘衊鏇獵) = 獵窪餘淵鏇膚鏇鹽製鬱 積壓觸衊選膚積淵繭餘 (艱憲築蓋選餘簾膚製窪 ) | 积极 | 2021-05-18 | |||
venetoclax+Isavuconazole | 鹽壓壓獵鏇鹽鹽廠膚構(願醖築願顧衊餘衊鏇獵) = 築膚醖衊構觸鹹鏇壓構 積壓觸衊選膚積淵繭餘 (艱憲築蓋選餘簾膚製窪 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用